Dunbar Ivy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8397837/publications.pdf

Version: 2024-02-01

198 papers	9,258 citations	53794 45 h-index	45317 90 g-index
209 all docs	209 docs citations	209 times ranked	4763 citing authors

#	Article	IF	Citations
1	Pediatric Pulmonary Hypertension. Circulation, 2015, 132, 2037-2099.	1.6	879
2	Pediatric Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D117-D126.	2.8	451
3	Clinical features of paediatric pulmonary hypertension: a registry study. Lancet, The, 2012, 379, 537-546.	13.7	441
4	Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. European Respiratory Journal, 2019, 53, 1801916.	6.7	399
5	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension. Circulation, 2012, 125, 324-334.	1.6	327
6	Survival in Childhood Pulmonary Arterial Hypertension. Circulation, 2012, 125, 113-122.	1.6	321
7	Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clinical Pharmacology and Therapeutics, 2003, 73, 372-382.	4.7	299
8	Effects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2005, 46, 697-704.	2.8	245
9	Effects of Long-Term Sildenafil Treatment for Pulmonary Hypertension in Infants with Chronic Lung Disease. Journal of Pediatrics, 2009, 154, 379-384.e2.	1.8	235
10	A Consensus Approach to the Classification of Pediatric Pulmonary Hypertensive Vascular Disease: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulmonary Circulation, 2011, 1, 286-298.	1.7	215
11	Pulmonary Vascular Effects of Inhaled Nitric Oxide and Oxygen Tension in Bronchopulmonary Dysplasia. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1006-1013.	5.6	181
12	Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2008, 51, 161-169.	2.8	178
13	STARTS-2. Circulation, 2014, 129, 1914-1923.	1.6	175
14	Evaluation and Management of Pulmonary Hypertension in Children with Bronchopulmonary Dysplasia. Journal of Pediatrics, 2017, 188, 24-34.e1.	1.8	175
15	Pulmonary vascular input impedance is a combined measure of pulmonary vascular resistance and stiffness and predicts clinical outcomes better than pulmonary vascular resistance alone in pediatric patients with pulmonary hypertension. American Heart Journal, 2008, 155, 166-174.	2.7	142
16	Survival Differences in Pediatric Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2014, 63, 2159-2169.	2.8	123
17	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 227-238.	10.7	122
18	Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. Genome Medicine, 2018, 10, 56.	8.2	112

#	Article	IF	Citations
19	Brain Natriuretic Peptide Levels in Managing Pediatric Patients With Pulmonary Arterial Hypertension. Chest, 2009, 135, 745-751.	0.8	103
20	Long-Term Outcomes in Children With Pulmonary Arterial Hypertension Treated With Bosentan in Real-World Clinical Settings. American Journal of Cardiology, 2010, 106, 1332-1338.	1.6	101
21	Initial Experience With Tadalafil in Pediatric Pulmonary Arterial Hypertension. Pediatric Cardiology, 2012, 33, 683-688.	1.3	99
22	Echocardiography in Pediatric Pulmonary Hypertension. Frontiers in Pediatrics, 2014, 2, 124.	1.9	99
23	Inhaled Nitric Oxide as a Preoperative Test (INOP Test I). Circulation, 2002, 106, .	1.6	97
24	Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI). Pulmonary Circulation, 2019, 9, 1-32.	1.7	96
25	Four- and Seven-Year Outcomes of Patients With Congenital Heart Diseaseâ€“Associated Pulmonary Arterial Hypertension (from the REVEAL Registry). American Journal of Cardiology, 2014, 113, 147-155.	1.6	95
26	Functional Classification of Pulmonary Hypertension in Children: Report from the PVRI Pediatric Taskforce, Panama 2011. Pulmonary Circulation, 2011, 1, 280-285.	1.7	92
27	Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart, 2015, 101, 1792-1799.	2.9	87
28	Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. Pediatric Pulmonology, 2013, 48, 27-34.	2.0	86
29	Right Ventricular to Left Ventricular Diameter Ratio at End-Systole in Evaluating Outcomes in Children with Pulmonary Hypertension. Journal of the American Society of Echocardiography, 2014, 27, 172-178.	2.8	84
30	Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. American Journal of Cardiology, 2004, 93, 943-946.	1.6	83
31	Clinical Characteristics and Risk Factors for Developing Pulmonary Hypertension in Children with Down Syndrome. Journal of Pediatrics, 2018, 202, 212-219.e2.	1.8	81
32	Transition of Stable Pediatric Patients With Pulmonary Arterial Hypertension from Intravenous Epoprostenol to Intravenous Treprostinil. American Journal of Cardiology, 2007, 99, 696-698.	1.6	78
33	Closed-Hub Systems with Protected Connections and the Reduction of Risk of Catheter-Related Bloodstream Infection in Pediatric Patients Receiving Intravenous Prostanoid Therapy for Pulmonary Hypertension. Infection Control and Hospital Epidemiology, 2009, 30, 823-829.	1.8	70
34	Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2016, 67, 1312-1323.	2.8	67
35	High-Altitude Pulmonary Edema in Children With Underlying Cardiopulmonary Disorders and Pulmonary Hypertension Living at Altitude. JAMA Pediatrics, 2004, 158, 1170.	3.0	64
36	Children with pulmonary arterial hypertension and prostanoid therapy: Long-term hemodynamics. Journal of Heart and Lung Transplantation, 2013, 32, 546-552.	0.6	62

#	Article	IF	Citations
37	Impact of Pulmonary Hemodynamics and Ventricular Interdependence on Left Ventricular Diastolic Function in Children With Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	62
38	Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2002, 282, L703-L712.	2.9	60
39	Use of Myocardial Performance Index in Pediatric Patients with Idiopathic Pulmonary Arterial Hypertension. Journal of the American Society of Echocardiography, 2006, 19, 21-27.	2.8	57
40	3D echocardiographic evaluation of right ventricular function and strain: a prognostic study in paediatric pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2018, 19, 1026-1033.	1.2	57
41	Drug Treatment of Pulmonary Hypertension in Children. Paediatric Drugs, 2014, 16, 43-65.	3.1	51
42	B-type Natriuretic Peptide and Amino-terminal Pro-B-type Natriuretic Peptide in Pediatric Patients with Pulmonary Arterial Hypertension. Congenital Heart Disease, 2012, 7, 259-267.	0.2	50
43	Cardiac Catheterization in Children with Pulmonary Hypertensive Vascular Disease: Consensus Statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces. Pulmonary Circulation, 2016, 6, 118-125.	1.7	49
44	Utility of cardiopulmonary stress testing in assessing disease severity in children with pulmonary arterial hypertension. American Journal of Cardiology, 2005, 95, 697-699.	1.6	48
45	Tissue Doppler Imaging Predicts Adverse Outcome in Children withÂIdiopathic Pulmonary Arterial Hypertension. Journal of Pediatrics, 2012, 161, 1126-1131.e2.	1.8	47
46	Left Ventricular Myocardial Function in Children With Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2015, 8, .	2.6	45
47	Repair of Congenital Heart Disease with Associated Pulmonary Hypertension in Children: What are the Minimal Investigative Procedures? Consensus Statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI). Pulmonary Circulation, 2014, 4, 330-341.	1.7	44
48	Pulmonary Hypertension in Children. Cardiology Clinics, 2016, 34, 451-472.	2.2	43
49	Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry. European Respiratory Journal, 2022, 59, 2003337.	6.7	43
50	Prostacyclin in the intensive care setting. Pediatric Critical Care Medicine, 2010, 11, S41-S45.	0.5	41
51	Right Atrial Deformation in Predicting Outcomes in Pediatric Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	41
52	Medical Therapy for Pediatric Pulmonary Arterial Hypertension. Journal of Pediatrics, 2010, 157, 528-532.	1.8	40
53	Sildenafil Increases Systemic Saturation and Reduces Pulmonary Artery Pressure in Patients with Failing Fontan Physiology. Congenital Heart Disease, 2009, 4, 107-111.	0.2	39
54	Relationship Between Left Ventricular Geometry and Invasive Hemodynamics in Pediatric Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2020, 13, e009825.	2.6	39

#	Article	IF	Citations
55	FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. International Journal of Cardiology, 2016, 202, 52-58.	1.7	37
56	Clinical Perspectives with Longâ€Term Pulsed Inhaled Nitric Oxide for the Treatment of Pulmonary Arterial Hypertension. Pulmonary Circulation, 2012, 2, 139-147.	1.7	36
57	Proximal pulmonary vascular stiffness as a prognostic factor in children with pulmonary arterial hypertension. European Heart Journal Cardiovascular Imaging, 2019, 20, 209-217.	1.2	36
58	Circulating Myeloid-Derived Suppressor Cells Are Increased and Activated in Pulmonary Hypertension. Chest, 2012, 141, 944-952.	0.8	35
59	Clinical Trials in Neonates and Children: Report of the Pulmonary Hypertension Academic Research Consortium Pediatric Advisory Committee. Pulmonary Circulation, 2013, 3, 252-266.	1.7	35
60	Ventilatory efficiency slope correlates with functional capacity, outcomes, and disease severity in pediatric patients with pulmonary hypertension. International Journal of Cardiology, 2013, 169, 445-448.	1.7	33
61	RV stroke work in children with pulmonary arterial hypertension: estimation based on invasive haemodynamic assessment and correlation with outcomes. Heart, 2014, 100, 1342-1347.	2.9	33
62	Pulmonary vein stenosis: Treatment and challenges. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 2169-2176.	0.8	33
63	Performance of Cavopulmonary Palliation at Elevated Altitude. Circulation, 2008, 118, S177-81.	1.6	31
64	Circulating Cytokines and Growth Factors in Pediatric Pulmonary Hypertension. Mediators of Inflammation, 2012, 2012, 1-7.	3.0	31
65	Non-invasive determination by cardiovascular magnetic resonance of right ventricular-vascular coupling in children and adolescents with pulmonary hypertension. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 81.	3.3	31
66	Hemodynamic response to ketamine in children with pulmonary hypertension. Paediatric Anaesthesia, 2016, 26, 102-108.	1.1	30
67	Food and Drug Administration (FDA) Postmarket Reported Side Effects and Adverse Events Associated with Pulmonary Hypertension Therapy in Pediatric Patients. Pediatric Cardiology, 2013, 34, 1628-1636.	1.3	29
68	Echocardiographic Estimation of Right Ventricular Stroke Work in Children with Pulmonary Arterial Hypertension: Comparison with Invasive Measurements. Journal of the American Society of Echocardiography, 2015, 28, 1350-1357.	2.8	29
69	Apparent Aortic Stiffness in Children With Pulmonary Arterial Hypertension. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	29
70	Right Ventricular-Arterial Coupling Ratio Derived From 3-Dimensional Echocardiography Predicts Outcomes in Pediatric Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2019, 12, e008176.	2.6	29
71	Pulmonary hypertension in children with Down syndrome. Pediatric Pulmonology, 2021, 56, 621-629.	2.0	29
72	Noninvasive wave intensity analysis predicts functional worsening in children with pulmonary arterial hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H968-H977.	3.2	28

#	Article	IF	Citations
73	Biomarkers for Pediatric Pulmonary Arterial Hypertension â€“ A Call to Collaborate. Frontiers in Pediatrics, 2014, 2, 7.	1.9	27
74	Three-dimensional Echocardiography of Right Ventricular Function Correlates with Severity of Pediatric Pulmonary Hypertension. Congenital Heart Disease, 2016, 11, 562-569.	0.2	27
75	Reduced proximal aortic compliance and elevated wall shear stress after early repair of tetralogy of Fallot. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 2239-2249.	0.8	27
76	Advances in pediatric pulmonary arterial hypertension. Current Opinion in Cardiology, 2012, 27, 70-81.	1.8	26
77	Effect of electrical dyssynchrony on left and right ventricular mechanics in children with pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 870-878.	0.6	25
78	Clinical Classification in Pediatric Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. Pulmonary Circulation, 2016, 6, 302-312.	1.7	24
79	Characterization of CMR-derived haemodynamic data in children with pulmonary arterial hypertension. European Heart Journal Cardiovascular Imaging, 2016, 18, jew152.	1.2	24
80	A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTUREâ€3. British Journal of Clinical Pharmacology, 2017, 83, 1734-1744.	2.4	24
81	Pulmonary-to-Systemic Arterial Shunt toÂTreat Children With Severe PulmonaryÂHypertension. Journal of the American College of Cardiology, 2021, 78, 468-477.	2.8	24
82	Acute Pulmonary Vasodilator Testing With Inhaled Treprostinil in Children With Pulmonary Arterial Hypertension. Pediatric Cardiology, 2013, 34, 1006-1012.	1.3	23
83	Persistent Challenges in Pediatric Pulmonary Hypertension. Chest, 2016, 150, 226-236.	0.8	23
84	Pulmonary arterial hypertension in children after neonatal arterial switch operation. Heart, 2017, 103, 1244-1249.	2.9	23
85	Pulmonary Arterial Capacitance Index Is a Strong Predictor for Adverse Outcome in Children with Idiopathic and Heritable Pulmonary Arterial Hypertension. Journal of Pediatrics, 2017, 180, 75-79.e2.	1.8	23
86	Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multiâ€Stakeholder Think Tank. Journal of the American Heart Association, 2018, 7, .	3.7	23
87	New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017. Journal of the American Heart Association, 2019, 8, e011306.	3.7	23
88	Plasma proteomics of differential outcome to longâ€term therapy in children with idiopathic pulmonary arterial hypertension. Proteomics - Clinical Applications, 2012, 6, 257-267.	1.6	22
89	Diagnosis and Treatment of Severe Pediatric Pulmonary Hypertension. Cardiology in Review, 2001, 9, 227-237.	1.4	21
90	Drug Treatment of Pulmonary Hypertension in Children. Paediatric Drugs, 2020, 22, 123-147.	3.1	21

#	Article	IF	Citations
91	Growth in children with pulmonary arterial hypertension: a longitudinal retrospective multiregistry study. Lancet Respiratory Medicine,the, 2016, 4, 281-290.	10.7	20
92	Differences in pulmonary arterial flow hemodynamics between children and adults with pulmonary arterial hypertension as assessed by 4D-flow CMR studies. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H1091-H1104.	3.2	20
93	The Left Heart, Systemic Circulation, and Bronchopulmonary Dysplasia: Relevance to Pathophysiology and Therapeutics. Journal of Pediatrics, 2020, 225, 13-22.e2.	1.8	20
94	Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension. Chest, 2020, 157, 1606-1616.	0.8	20
95	Pediatric Cardiac Intensive Care Society 2014 Consensus Statement. Pediatric Critical Care Medicine, 2016, 17, S89-S100.	0.5	19
96	Treatment of pediatric pulmonary arterial hypertension: A focus on the NOâ€šGCâ€cGMP pathway. Pediatric Pulmonology, 2019, 54, 1516-1526.	2.0	19
97	Abnormal aortic flow conduction is associated with increased viscous energy loss in patients with repaired tetralogy of Fallot. European Journal of Cardio-thoracic Surgery, 2020, 57, 588-595.	1.4	18
98	Novel measures of left ventricular electromechanical discoordination predict clinical outcomes in children with pulmonary arterial hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H401-H412.	3.2	18
99	Obesity in Pulmonary Arterial Hypertension. The Pulmonary Hypertension Association Registry. Annals of the American Thoracic Society, 2021, 18, 229-237.	3.2	18
100	Impact of different coarctation therapies on aortic stiffness: phase-contrast MRI study. International Journal of Cardiovascular Imaging, 2018, 34, 1459-1469.	1.5	17
101	Abnormal left ventricular flow organization following repair of tetralogy of Fallot. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 1008-1015.	0.8	17
102	Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry. Pulmonary Circulation, 2021, 11, 1-10.	1.7	17
103	Computational simulation of the pulmonary arteries and its role in the study of pediatric pulmonary hypertension. Progress in Pediatric Cardiology, 2010, 30, 63-69.	0.4	16
104	Circulating miRNAs in Pediatric Pulmonary Hypertension Show Promise as Biomarkers of Vascular Function. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-11.	4.0	16
105	Update on noninvasive imaging of right ventricle dysfunction in pulmonary hypertension. Cardiovascular Diagnosis and Therapy, 2020, 10, 1604-1624.	1.7	16
106	Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine. Annals of the American Thoracic Society, 2022, 19, 227-237.	3.2	16
107	Endothelin B Receptor Blockade Attenuates Pulmonary Vasodilation in Oxygen-Ventilated Fetal Lambs. Neonatology, 2004, 86, 155-159.	2.0	15
108	Aortic stiffness in adolescent Turner and Marfan syndrome patients. European Journal of Cardio-thoracic Surgery, 2018, 54, 926-932.	1.4	15

#	Article	IF	Citations
109	Diagnosis, Evaluation and Treatment of Pulmonary Arterial Hypertension in Children. Children, 2018, 5, 44.	1.5	15
110	Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. Journal of Heart and Lung Transplantation, 2020, 39, 945-953.	0.6	15
111	Progress in the diagnosis and management of pulmonary hypertension in children. Current Opinion in Pediatrics, 2014, 26, 527-535.	2.0	14
112	Tricuspid annular plane systolic excursion is preserved in young patients with pulmonary hypertension except when associated with repaired congenital heart disease. European Heart Journal Cardiovascular Imaging, 2017, 18, 459-466.	1.2	14
113	Oral treprostinil in transition or as addâ€on therapy in pediatric pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-8.	1.7	14
114	Ventricular interactions and electromechanical dyssynchrony after Ross and Ross-Konno operations. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 509-517.	0.8	14
115	Influence of aortic stiffness on ventricular function in patients with Fontan circulation. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 699-707.	0.8	13
116	Increased systolic vorticity in the left ventricular outflow tract is associated with abnormal aortic flow formations in Tetralogy of Fallot. International Journal of Cardiovascular Imaging, 2020, 36, 691-700.	1.5	13
117	Right ventricular area strain from 3-dimensional echocardiography: Mechanistic insight of right ventricular dysfunction in pediatric pulmonary hypertension. Journal of Heart and Lung Transplantation, 2021, 40, 138-148.	0.6	13
118	High-degree Norwood neoaortic tapering is associated with abnormal flow conduction and elevated flow-mediated energy loss. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 1791-1804.	0.8	13
119	Evaluation of Circulating Proteins and Hemodynamics Towards Predicting Mortality in Children with Pulmonary Arterial Hypertension. PLoS ONE, 2013, 8, e80235.	2.5	13
120	High Altitude Pulmonary Edema in Children: A Single Referral Center Evaluation. Journal of Pediatrics, 2019, 210, 106-111.	1.8	12
121	Usefulness of 4D-Flow MRI in Mapping Flow Distribution Through Failing Fontan Circulation Prior to Cardiac Intervention. Pediatric Cardiology, 2019, 40, 1093-1096.	1.3	12
122	Parameters of Right Ventricular Function Reveal Ventricular-Vascular Mismatch as Determined by Right Ventricular Stroke Work versus Pulmonary Vascular Resistance in Children with Pulmonary Hypertension. Journal of the American Society of Echocardiography, 2020, 33, 218-225.	2.8	12
123	Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 761-764.	5.6	12
124	Shortâ€Term Effects of Inhaled Nitric Oxide on Right Ventricular Flow Hemodynamics by 4â€Dimensionalâ€“Flow Magnetic Resonance Imaging in Children With Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2021, 10, e020548.	3.7	12
125	Measuring Flow Hemodynamic Indices and Oxygen Consumption in Children with Pulmonary Hypertension: A Comparison of Catheterization and Phase-Contrast MRI. Pediatric Cardiology, 2018, 39, 268-274.	1.3	11
126	Meaningful and feasible composite clinical worsening definitions in paediatric pulmonary arterial hypertension: An analysis of the TOPP registry. International Journal of Cardiology, 2019, 289, 110-115.	1.7	11

#	Article	IF	Citations
127	Frequency of Reduced Left Ventricular Contractile Efficiency and Discoordinated Myocardial Relaxation in Patients Aged 16 to 21 Years With Type 1 Diabetes Mellitus (from the Emerald Study). American Journal of Cardiology, 2020, 128, 45-53.	1.6	11
128	Metalloproteinases and their inhibitors are associated with pulmonary arterial stiffness and ventricular function in pediatric pulmonary hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H242-H252.	3.2	11
129	Pulmonary Hypertension in the Population with Down Syndrome. Cardiology and Therapy, 2022, 11, 33-47.	2.6	11
130	Assessment of Nâ€Terminal Prohormone Bâ€Type Natriuretic Peptide as a Measure of Vascular and Ventricular Function in Pediatric Pulmonary Arterial Hypertension. Pulmonary Circulation, 2015, 5, 658-666.	1.7	10
131	Right Ventricular Tissue Doppler Myocardial Performance Index in Children with Pulmonary Hypertension: Relation to Invasive Hemodynamics. Pediatric Cardiology, 2018, 39, 98-104.	1.3	10
132	Efficacy and safety of tadalafil in a pediatric population with pulmonary arterial hypertension: phase 3 randomized, doubleâ€blind placeboâ€controlled study. Pulmonary Circulation, 2021, 11, 1-8.	1.7	10
133	Structural and Biomechanical Adaptations of Right Ventricular Remodelingâ€"In Pulmonary Arterial Hypertensionâ€"Reduces Left Ventricular Rotation During Contraction: A Computational Study. Journal of Biomechanical Engineering, 2019, 141, .	1.3	9
134	Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension. Journal of Pediatrics, 2020, 223, 164-169.e1.	1.8	9
135	Pediatric Pulmonary Arterial Hypertension. Pediatric Clinics of North America, 2020, 67, 903-921.	1.8	9
136	The left ventricle undergoes biomechanical and gene expression changes in response to increased right ventricular pressure overload. Physiological Reports, 2020, 8, e14347.	1.7	9
137	Patients with Fontan circulation have abnormal aortic wave propagation patterns: A wave intensity analysis study. International Journal of Cardiology, 2021, 322, 158-167.	1.7	9
138	Right Atrial Conduit Phase Emptying Predicts Risk of Adverse Events in Pediatric Pulmonary Arterial Hypertension. Journal of the American Society of Echocardiography, 2020, 33, 1006-1013.	2.8	8
139	Update on pediatric pulmonary arterial hypertension. Current Opinion in Cardiology, 2021, 36, 67-79.	1.8	8
140	A Zero-Dimensional Model and Protocol for Simulating Patient-Specific Pulmonary Hemodynamics From Limited Clinical Data. Journal of Biomechanical Engineering, 2016, 138, .	1.3	7
141	Acute vasoreactivity testing in pediatric idiopathic pulmonary arterial hypertension: an international survey on current practice. Pulmonary Circulation, 2019, 9, 1-9.	1.7	7
142	Flow profile characteristics in Fontan circulation are associated with the single ventricle dilation and function: principal component analysis study. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H1032-H1040.	3.2	7
143	Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Realâ€world experience. Pediatric Pulmonology, 2022, 57, 724-733.	2.0	7
144	Evaluation of predictive models for six minute walk test among children with pulmonary hypertension. International Journal of Cardiology, 2017, 227, 393-398.	1.7	6

#	Article	IF	Citations
145	Transvenous implantation of the Occlutech Atrial Flow Regulator: Preliminary results from swine models. Congenital Heart Disease, 2019, 14, 819-831.	0.2	6
146	Tale of 2 Endothelin Receptor Antagonists in Eisenmenger Syndrome. Circulation, 2019, 139, 64-66.	1.6	6
147	Pediatric pulmonary hypertension: insulin-like growth factor-binding protein 2 is a novel marker associated with disease severity and survival. Pediatric Research, 2020, 88, 850-856.	2.3	6
148	ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening. Chest, 2021, 160, 297-306.	0.8	6
149	Children with kawasaki disease present elevated stiffness of great arteries: Phaseâ€contrast MRI study. Journal of Magnetic Resonance Imaging, 2018, 48, 1228-1236.	3.4	5
150	Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry. Pulmonary Circulation, 2020, 10, 1-8.	1.7	5
151	Longitudinal assessment of right atrial conduit fraction provides additional insight to predict adverse events in pediatric pulmonary hypertension. International Journal of Cardiology, 2021, 329, 242-245.	1.7	5
152	Abnormal pulmonary flow is associated with impaired right ventricular coupling in patients with COPD. International Journal of Cardiovascular Imaging, 2021, 37, 3039-3048.	1.5	5
153	The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension. ERJ Open Research, 2021, 7, 00378-2021.	2.6	5
154	Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Diseaseâ€“Associated Pulmonary Hypertension. Journal of the American Heart Association, 2021, 10, e021409.	3.7	5
155	Hemodynamic and prognostic impact of the diastolic pulmonary arterial pressure in children with pulmonary arterial hypertensionâ€”a registry-based analysis. Cardiovascular Diagnosis and Therapy, 2021, 11, 1037-1047.	1.7	4
156	Technical Feasibility on the Use of Optical Coherence Tomography in the Evaluation of Pediatric Pulmonary Venous Stenosis. Pediatric Cardiology, 2022, , 1.	1.3	4
157	Abnormal flow conduction through pulmonary arteries is associated with right ventricular volume and function in patients with repaired tetralogy of Fallot: does flow quality affect afterload?. European Radiology, 2023, 33, 302-311.	4.5	4
158	Threeâ€Ðimensional Echocardiography Enhances Diagnostic Accuracy of Supramitral Ring. Echocardiography, 2015, 32, 1048-1050.	0.9	3
159	Beyond the 6-Minute Walk Test for Assessing Pediatric Pulmonary Hypertension. Chest, 2015, 148, 576-577.	0.8	3
160	Hospitalizations of Children With Pulmonary Hypertension: Implications for Improving Care. Pediatrics, 2015, 136, 392-393.	2.1	3
161	Altered Peripheral Blood Myeloid Cell Subpopulations in Children With Down Syndrome and Pulmonary Hypertension. Journal of Pediatric Hematology/Oncology, 2017, 39, 158-159.	0.6	3
162	Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension. Journal of Cardiovascular Pharmacology, 2020, 76, 94-100.	1.9	3

#	Article	IF	Citations
163	Practice patterns of pulmonary hypertension secondary to left heart disease among pediatric pulmonary hypertension providers. Pulmonary Circulation, 2021, 11, 1-8.	1.7	3
164	Pulmonary arterial banding in mice may be a suitable model for studies on ventricular mechanics in pediatric pulmonary arterial hypertension. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 66.	3.3	3
165	Ventricularâ€“vascular coupling is predictive of adverse clinical outcome in paediatric pulmonary arterial hypertension. Open Heart, 2021, 8, e001611.	2.3	3
166	Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension. Journal of Pediatrics, 2022, 241, 68-76.e3.	1.8	3
167	Repolarization Dispersion Is Associated With Diastolic Electromechanical Discoordination in Children With Pulmonary Arterial Hypertension. Journal of the American Heart Association, 2022, 11, e024787.	3.7	3
168	2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil. Journal of the American College of Cardiology, 2017, 70, 495-503.	2.8	2
169	The failing right ventricle: Where do we go from here. Acta Physiologica, 2020, 229, e13523.	3.8	2
170	Monitoring and evaluation of the surgical Potts shunt physiology using 4-dimensional flow magnetic resonance imaging. Journal of Thoracic and Cardiovascular Surgery, 2021, , .	0.8	2
171	High-Altitude Pulmonary Edema in Colorado Children: A Cross-Sectional Survey and Retrospective Review. High Altitude Medicine and Biology, 2022, 23, 119-124.	0.9	2
172	The Anesthetic Challenges of Lung Biopsyâ€“Associated Intrathoracic Hemorrhage in a Child With Suprasystemic Pulmonary Hypertension. Seminars in Cardiothoracic and Vascular Anesthesia, 2017, 21, 172-177.	1.0	1
173	Predictive value of presuperior cavopulmonary anastomosis cardiac catheterization at increased altitude. Congenital Heart Disease, 2018, 13, 311-318.	0.2	1
174	Right Heart Failure in Pediatric Pulmonary Hypertension. , 2018, , 399-412.		1
175	Segmental Pulmonary Hypertension in Children with Congenital Heart Disease. Medicina (Lithuania), 2020, 56, 492.	2.0	1
176	A Randomized Study of Safety and Efficacy of Two Doses of Ambrisentan to Treat Pulmonary Arterial Hypertension in Pediatric Patients Aged 8 Years up to 18 Years. Journal of Pediatrics: X, 2020, 5, 100055.	1.1	1
177	Pediatric Pulmonary Arterial Hypertension: Evaluation and Treatment. Current Treatment Options in Pediatrics, 2020, 6, 12-28.	0.6	1
178	Echocardiographic Changes and Long-Term Clinical Outcomes in Pediatric Patients With Pulmonary Arterial Hypertension Treated With Bosentan for 72 Weeks: A Post-hoc Analysis From the FUTURE 3 Study. Frontiers in Pediatrics, 2021, 9, 681538.	1.9	1
179	Serum endostatin as a genetically-influenced biomarker in PAH. , 2019, , .		1
180	A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension. Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery, 2010, 26, 206-218.	0.0	1

#	Article	IF	Citations
181	Hepatomaâ€derived growth factor is associated with pulmonary vascular remodeling and PAH disease severity and survival. Pulmonary Circulation, 2022, 12, e12007.	1.7	1
182	Pediatric Cardiology. Pediatric Clinics of North America, 2020, 67, i.	1.8	0
183	Pediatric Cardiology: From Basics to Innovation. Pediatric Clinics of North America, 2020, 67, xvii-xviii.	1.8	0
184	MicroRNA as a Biomarker in Pediatric Pulmonary Hypertension. Pediatric Critical Care Medicine, 2020, 21, 393-394.	0.5	0
185	Partial occlusion of PDA in a patient with severe pulmonary hypertension using a manually fenestrated and stented muscular VSD device. Progress in Pediatric Cardiology, 2020, 59, 101229.	0.4	0
186	Reply to Commentary: Can't flow down: More 4-dimensional flow magnetic resonance imaging studies are needed in congenital heart disease. Journal of Thoracic and Cardiovascular Surgery, 2020, 160, 1019-1020.	0.8	0
187	B-PO01-103 IMMEDIATE CHANGE IN SYSTOLIC STRETCH FRACTION PREDICTS RESPONSIVENESS TO CARDIAC RESYNCHRONIZATION THERAPY IN PATIENTS WITH CONGENITAL HEART DISEASE. Heart Rhythm, 2021, 18, S92.	0.7	0
188	Chronic Pulmonary Hypertension. , 2009, , 483-505.		0
189	Pediatric PH: New Challenges and Perspectives. Advances in Pulmonary Hypertension, 2011, 10, 78-78.	0.1	0
190	Idiopathic pulmonary arterial hypertension in children. , 2011, , 559-571.		0
191	The Pediatric Sildenafil Trial. Advances in Pulmonary Hypertension, 2012, 10, 215-216.	0.1	0
192	Abstract 15413: Comparison of Right Ventricular Functional Indices Using Two-dimensional and Three-dimensional Echocardiography to Predict Outcomes in Pediatric Pulmonary Hypertension. Circulation, 2015, 132, .	1.6	0
193	Complete Atrioventricular Septal Defects. , 2020, , 173-184.		0
194	Acute Pulmonary Hypertension. , 2020, , 455-464.		0
195	Chronic Pulmonary Hypertension. , 2020, , 465-489.		0
196	Ebsteinâ€™s Disease of the Tricuspid Valve. , 2020, , 405-417.		0
197	Abstract 13708: Right Ventricular Strain Comparison Between Quantification Software in Pediatric Normal and Pulmonary Hypertension Patients. Circulation, 2020, 142, .	1.6	0
198	An Acute Hyperoxia Test Predicts Survival in Children with Pulmonary Hypertension Living at High Altitude. High Altitude Medicine and Biology, 2021, 22, 395-405.	0.9	0